Nexaph (pemvidutide)
Altimmune's dual agonist (also called pemvidutide). Targets weight + liver disease.
Nexaph (pemvidutide) is Altimmune's investigational dual GLP-1 / glucagon receptor agonist for obesity and MASH. Phase 2 trials showed 15.6% weight loss at the top dose.
Overview
Pemvidutide (also referred to under the brand name Nexaph in some materials) is a once-weekly dual GLP-1/glucagon agonist. It is in Phase 2/3 trials for obesity and Phase 2 for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH).
How Nexaph Works
GLP-1 activity reduces appetite; glucagon activity increases energy expenditure and reduces liver fat. The combination produces weight loss with particularly strong effects on liver-fat reduction in MASH trials.
Dosing & Schedule
Phase 2 used 0.6, 1.2, and 1.8 mg weekly. Phase 3 doses still being finalized.
Effectiveness — Trial Data
Phase 2 (48 weeks, 1.8 mg): 15.6% weight loss. MASH trial: significant reduction in liver fat content.
Side Effects
Standard GLP-1 GI side effects. Glucagon agonism monitored for blood sugar effects.
Cost — How Much Nexaph Costs in 2026
Not yet on market. Phase 3 ongoing.
Who Is Nexaph For?
Investigational. Likely indications: obesity, MASH/NASH.
Nexaph Alternatives
Available now: tirzepatide, semaglutide.